---
layout: default
title: Nitrous Oxide
parent: 僅模型預測 (L5)
nav_order: 974
evidence_level: L5
indication_count: 1
---

# Nitrous Oxide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Nitrous Oxide: From No Established Indication to Benign Prostatic Hyperplasia

## One-Sentence Summary

Nitrous oxide is an inhaled anesthetic/analgesic gas with no marketed indication in Taiwan and no formally recorded original indication in this evidence pack. The TxGNN model predicts potential effectiveness for **Benign Prostatic Hyperplasia (BPH)**, but this is currently supported by **model prediction only** — the single related clinical trial evaluates procedural anxiolysis during prostate biopsy, not treatment of BPH itself.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (no approved indication text on file) |
| Predicted New Indication | Benign Prostatic Hyperplasia |
| TxGNN Prediction Score | 99.52% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, nitrous oxide is an inhaled anesthetic/analgesic gas whose known pharmacology involves NMDA receptor antagonism and opioid-like analgesic effects — mechanisms unrelated to prostate smooth muscle tone (α-adrenergic pathways) or androgen/DHT metabolism, which are the established pathophysiological targets in BPH treatment.

The only supporting clinical trial evaluates self-administered nitrous oxide for reducing anxiety and pain during transrectal prostate biopsy — a procedural sedation use case in a BPH-adjacent patient population, not a treatment aimed at BPH symptoms (e.g., IPSS score, uroflowmetry, prostate volume). The repurposing rationale explicitly notes there is no direct mechanistic link between nitrous oxide and BPH pathophysiology (bladder outlet obstruction, prostatic hyperplasia); the association is indirect, based only on "anesthetic gas used during urologic procedures."

Given this gap between the drug's known pharmacology and the target disease's pathophysiology, this prediction should be treated as a data-driven hypothesis requiring substantial further mechanistic and clinical investigation before any development consideration.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT05803096](https://clinicaltrials.gov/study/NCT05803096) | Phase 4 | Completed | 143 | Evaluated self-administered nitrous oxide during transrectal prostate biopsy to reduce patient anxiety and pain — a procedural sedation study, not a BPH treatment trial (relevance graded C/low). |

---

## Literature Evidence

Currently no related literature available. (Three PMIDs retrieved — 9223887, 4171323, 4108916 — are case reports on unrelated anesthesia topics and were not assessed as relevant to BPH.)

---

## US Market Information

Nitrous oxide currently has no approved license or marketed product on file (0 licenses recorded, market status: 未上市).

---

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are currently unavailable — flagged as a Blocking data gap for TFDA label information.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by TxGNN's model score (L5, S0 decision stage) with no mechanistically relevant clinical or literature evidence — the one available trial addresses procedural sedation, not BPH treatment, and there is no established pharmacological link between nitrous oxide and BPH pathophysiology.

**To proceed, the following is needed:**
- TFDA label/warnings and contraindication data (currently Blocking gap, required for any S1 safety review)
- Verified mechanism of action data via DrugBank (currently High-severity gap)
- Dedicated preclinical or clinical evidence directly evaluating nitrous oxide's effect on BPH symptoms/pathophysiology (current evidence only covers unrelated procedural use)
- Confirmation of route compatibility and dosing feasibility for a chronic condition like BPH, given nitrous oxide's typical acute/procedural use pattern
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

